DrugRisk Center: Yaz & Yasmin Warnings Extend to Generics as Well

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
yaz lawsuit
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking the brand name or generic version of Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

New York, NY (PRWEB) December 07, 2012

The Drug Risk Resource Center, a patient awareness group, is alerting women prescribed the birth control Yaz or Yasmin that experts have related both the brand name and generic versions of the drugs to risks of blood clots. Bayer recently announced they are settling many of the claims filed by patients.

The American College of Obstetricians and Gynecologists in October renewed warnings that birth control pills containing drospirenone, such as Yaz and Yasmin and generic versions, may have a higher risk of causing blood clots.*

Last year, the British Medical Journal published a study from the University of Copenhagen on October 25, 2011 which also linked the hormone in Yaz and similar generics to blood clots. The FDA released a study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" on October 27, 2011 indicating drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking the brand name or generic version of Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options. You may be eligible to file a Yaz lawsuit.

The German drug company Bayer, who makes Yaz and Yasmin, indicated in their latest financial report that they have settled approximately 3,500 Yaz lawsuits so far at a total cost of nearly $750 million, or an average of approximately $214,000 per case.**

The company also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

To handle the volume of claims, Yaz lawsuits were consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be due to taking generic or brand name Yaz or Yasmin can contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

The Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
**Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012


Contact